{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-140078","form_type":"8-K","ticker":"PHAT","cik":"0001783183","company_name":"Phathom Pharmaceuticals, Inc.","filed_at":"2023-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.548051+00:00","generated_at":"2026-06-15T06:49:30.230505+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Phathom Q1 net loss $37.8M, on track to resubmit Erosive GERD NDA this quarter","bullets":["Net loss $37.8M vs $40.7M YoY; operating expenses 36% lower than prior quarter due to cost controls after launch delay.","Cash $129.6M at Mar 31, 2023; additional $100M term loan available, $175M upon FDA approval of VOQUEZNA for Erosive GERD.","On track to resubmit Erosive GERD NDA this quarter; potential FDA approval and U.S. launch for Erosive GERD and H. pylori in Q4 2023.","Ph3 PHALCON-NERD-301 trial met primary endpoint; regulatory submission for Non-Erosive GERD expected H2 2023.","Coverage secured for 60% of commercial lives for VOQUEZNA TRIPLE PAK and DUAL PAK for H. pylori."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-140078","json":"https://secwatch.observer/filing/0001193125-23-140078.json","markdown":"https://secwatch.observer/filing/0001193125-23-140078.md","text":"https://secwatch.observer/filing/0001193125-23-140078.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783183/000119312523140078/0001193125-23-140078-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783183/000119312523140078/d457235d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T06:49:30.230505+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fcf2f2e0d860fff9340529d03ed412ed7c9ff7d1","claim":"Phathom Pharmaceuticals, Inc. reported the first quarter ended March 31, 2023 results: net income $37.8 million.","evidence_excerpt":"Net loss for the first quarter ended March 31, 2023 was $37.8 million, compared to $40.7 million for first quarter 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1783183/000119312523140078/0001193125-23-140078-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Net income","value":"$37.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}